Design Therapeutics (DSGN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Design Therapeutics (DSGN) is Neutral.

The composite score behind that read is -0.13, weighing +0.28 of bullish evidence against -0.18 bearish.

Design Therapeutics last closed at $12.42, +0.65% on the session.

Against the IVW growth benchmark the position is -0.27% over the forecast window.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

Design Therapeutics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Design Therapeutics in the 22nd percentile on return on equity, where 100 is best.

Design Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $772.26M.

StockMap tracks Design Therapeutics as the 138th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Design Therapeutics ranks 88th of 344 in the group, against a group median of -0.21.